Evidence map›Paper›PMID 40189852›Full record

SynthesisAnnals of Saudi medicine

High-dose statins for the prevention of recurrent ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.

Muhammed Siddique Shahid, Mariam Safwan Bourgleh, Adel Alharfi, Shahad Albariqi, Lamia Albalawi, Rema Alohali, Turki Albaqami, Moaz Safwan Bourgleh

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Muhammed Siddique ShahidFrom the Department of Clinical Sciences, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Mariam Safwan BourglehFrom the Department of Clinical Sciences, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.ORCID 0009-0004-2050-9055
Adel AlharfiFrom the Department of Clinical Sciences, College of Medicine, Tabuk University, Tabuk, Saudi Arabia.
Shahad AlbariqiFrom the Department of Clinical Sciences, College of Medicine, King Khalid University, Abha, Asir Province, Saudi Arabia.
Lamia AlbalawiFrom the Department of Clinical Sciences, College of Medicine, Tabuk University, Tabuk, Saudi Arabia.
Rema AlohaliFrom the Department of Clinical Sciences, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Turki AlbaqamiFrom the Department of Clinical Sciences, College of Medicine, Shaqra University, Shaqra, Riyadh, Saudi Arabia.
Moaz Safwan BourglehFrom the Department of Clinical Sciences, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIschemic stroke (IS) is a leading cause of disability and mortality, with fatal outcomes increased with recurrent strokes. This systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the safety and efficacy of high-dose statins for secondary IS prevention.

methodsThis review was regestered on PROSPERO (registration number: CRD42024574088). Cochrane methodology was followed in this review and comprehensively searched PubMed, Embase, Cochrane Library and clinicaltrial.gov, to include all RCTs conducted from 2004 to 2024, comparing high-dose statins (simvastatin ≥40 mg, atorvastatin ≥40 mg, and rosuvastatin ≥20 mg) with low-dose statins, placebo, or standard care. Outcomes of this review were recurrent IS reduction and adverse events reported in RCTs.

resultsNine RCTs involving 5,503 patients, with male patients ranging from 25.8% to 81.6% were included. Compared to controls, high-dose statins did not significantly reduce risks for secondary IS (OR 0.78, 95% CI [0.61, 1.00],

conclusionTreatment with high dose statins didn't reduce the risk of stroke recurrence or improve mortality, though further research is needed.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsIschemic StrokeSecondary PreventionAtorvastatinDose-Response Relationship, DrugFemaleHumansMaleRandomized Controlled Trials as TopicRecurrenceRosuvastatin CalciumSimvastatinAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumSimvastatin

Identifiers

PMID40189852
PMCPMC12542917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.